Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
This study was registered with ClinicalTrials.gov, number NCT02345226. Findings Between Jan 26, 2015, and Aug 27, 2015, 875 participants were randomly assigned and treated (438 with rilpivirine, emtricitabine, and tenofovir alafenamide and 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate). Viral suppression at week 48 was maintained in 394 (90%) of 438 participants assigned to the tenofovir alafenamide regimen and 402 (92%) of 437 assigned to the tenofovir disoproxil fumarate regimen (difference −2·0%, 95·001% CI −5·9 to 1·8), demonstrating non-inferiority. 56 (13%) of 438 in participants in the ri...
Source: The Lancet HIV - March 1, 2017 Category: Infectious Diseases Source Type: research
Efavirenz/emtricitabine/tenofovir disoproxil fumarate
(Source: Reactions Weekly)
Source: Reactions Weekly - December 31, 2016 Category: Drugs & Pharmacology Source Type: research
Trimethyl chitosan improves Anti-HIV effects of Atripla as a new nano-formulated drug.
Conclusion; The result showed that atripla-TMC conjugate does not have a significant cytotoxicity effect. Due to the higher inhibitory effect of nano-conjugate on viral replication, it can be used in lower concentration for antiviral treatment, which resulted in reduction of drug resistance and other side effects.
PMID: 27993121 [PubMed - as supplied by publisher] (Source: Current HIV Research)
Source: Current HIV Research - December 15, 2016 Category: Infectious Diseases Authors: Shohani S, Abdoli A, Khansarinejad B, Ardestani MS, Salimi-Asl M, Ghanbari M, Haj MS, Zabihollahi R, Mondanizadeh M Tags: Curr HIV Res Source Type: research
Short Communication: The Impact of Switching from Atripla to Darunavir/Ritonavir Monotherapy on Neurocognition, Quality of Life, and Sleep: Results from a Randomized Controlled Study
AIDS Research and Human Retroviruses Dec 2016, Vol. 32, No. 12: 1198-1201. (Source: AIDS Research and Human Retroviruses)
Source: AIDS Research and Human Retroviruses - November 30, 2016 Category: Infectious Diseases Authors: Juan Tiraboschi Lisa Hamzah Alastair Teague Ranjababu Kulasegaram Frank Post Isabelle Jendruleck Tammy Murray Julie Fox Source Type: research
Neuromyelitis optica in hiv: a case report and literature review
We present a case and review the literature.
A 49 year old lady of African descent with known HIV diagnosed in 2004 – compliant with her antiretroviral medication, Atripla – was admitted with a 3 week history of thoracic back pain, spreading paraesthesia and weakness involving both legs, and constipation. Examination revealed a spastic paraparesis, a sensory level at T3/4 on the right and reduced vibration sense to the iliac crests bilaterally. MRI spine revealed increased signal within the cord from T3–7 in keeping with a longitudinally extensive transverse myelitis. CSF was acellular with normal protein...
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Appleton, J. P., Kenton, A. Tags: Neurogastroenterology, Immunology (including allergy), HIV/AIDS, Cranial nerves, Multiple sclerosis, Pain (neurology), Spinal cord, Ophthalmology ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research
Bone Mineral Density and Vitamin D Levels in HIV Treatment-Na ïve African American Individuals Randomized to Receive HIV Drug Regimens.
CONCLUSIONS: Treatment of African American patients with HIV using EFV/FTC/TDF is associated with a reduction in BMD of the hip and sustained reductions of 25(OH)D not seen in the group that received RAL/DRV/r. This phenomenon may have long-term consequences on bone integrity in this population.
PMID: 27812717 [PubMed - in process] (Source: Southern Medical Journal)
Source: Southern Medical Journal - November 6, 2016 Category: Journals (General) Tags: South Med J Source Type: research
The Impact of Switching from Atripla to Darunavir/Ritonavir Monotherapy on Neurocognition, Quality of Life, and Sleep: Results from a Randomized Controlled Study
AIDS Research and Human Retroviruses , Vol. 0, No. 0. (Source: AIDS Research and Human Retroviruses)
Source: AIDS Research and Human Retroviruses - August 21, 2016 Category: Infectious Diseases Authors: Juan Tiraboschi Lisa Hamzah Alastair Teague Ranjababu Kulasegaram Frank Post Isabelle Jendruleck Tammy Murray Julie Fox Source Type: research
Administration of tenofovir disoproxil fumarate-based antiretroviral therapy in an HIV-infected patient following unilateral nephrectomy
We report the use of efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, once daily in a 47-year-old black man with a solitary kidney and human immunodeficiency virus (HIV). In 1990, he underwent radiation, chemotherapy, and ultimately, a unilateral nephrectomy for Wilms' tumor. Because of previous reports of tenofovir disoproxil fumarate-induced nephrotoxicity, our objective was to evaluate and monitor our patient's renal function over the course of 19 months based on serum creatinine, estimated creatinine clearance using the Cockroft-Gault equation, estimated glomerular filtration rate using the m...
Source: International Journal of STD and AIDS - July 31, 2016 Category: Global & Universal Authors: Biagi, M., Badowski, M., Chiampas, T., Young, J., Vaughn, P., Shicker, L., Patel, M. Tags: Case reports Source Type: research
Nephrotoxicity Associated with Concomitant Use of Ledipasvir ‐Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection
This article is protected by copyright. All rights reserved. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - June 30, 2016 Category: Drugs & Pharmacology Authors: Kristen L. Bunnell, Sonia Vibhakar, Robert C. Glowacki, Maureen A. Gallagher, Albert M. Osei, Gregory Huhn Tags: Case Report Source Type: research
Stability behaviour of antiretroviral drugs and their combinations. 3: Characterization of interaction products of emtricitabine and tenofovir disoproxil fumarate by mass spectrometry
Publication date: 5 September 2016 Source:Journal of Pharmaceutical and Biomedical Analysis, Volume 128 Author(s): Moolchand Kurmi, Dilip Kumar Singh, Shristy Tiwari, Parul Sharma, Saranjit Singh The present study investigated drug–drug interaction behaviour of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) under solid state stability test conditions. Six interaction products were separated and detected by high performance liquid chromatography coupled to photodiode array detector (HPLC-PDA) using C18 column. The same were characterized using LC-high resolution mass spectrometry (LC-HRMS), LC-m...
Source: Journal of Pharmaceutical and Biomedical Analysis - June 23, 2016 Category: Drugs & Pharmacology Source Type: research
Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects
Conclusions: After EFV/FTC/TDF to EVG/COBI/FTC/TDF switch, EVG and/or EFV exposures were in an active range. These findings support further evaluation of switching regimens in HIV-1 patients. (Source: JAIDS Journal of Acquired Immune Deficiency Syndromes)
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - June 17, 2016 Category: Infectious Diseases Tags: Clinical Science Source Type: research
Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy
Abstract: In epidemiologic studies, human immunodeficiency virus (HIV)-infected men on antiretroviral therapy (ART) are at higher risk of incident diabetes mellitus compared with women with similar treatment histories. We used metabolomics to determine whether a sex difference in plasma amino acids, acylcarnitines, and organic acids predictive of diabetes and impaired energy metabolism is present in HIV-infected persons on long-term ART.
We enrolled 70 HIV-infected adults (43% women) on efavirenz, tenofovir, and emtricitabine (Atripla) with HIV-1 RNA (Source: Medicine)
Source: Medicine - May 1, 2016 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Odefsey - Another NNRTI Combination for HIV
Date:
May 9, 2016
Issue #:
1494
Summary:
The FDA has approved Odefsey (Gilead), a once-daily,
fixed-dose combination of the non-nucleoside
reverse transcriptase inhibitor (NNRTI) rilpivirine
and the nucleoside/nucleotide reverse transcriptase
inhibitors (NRTIs) emtricitabine and tenofovir
alafenamide, for initial treatment of HIV-1 infection in
patients with HIV-1 RNA (viral load) ≤100,000 copies/mL or to repla...
Source: The Medical Letter - April 20, 2016 Category: Drugs & Pharmacology Authors: admin Tags: Atripla cobicistat Complera darunavir Descovy Efavirenz elvitegravir Emtricitabine Genvoya hepatitis b NNRTIs Odefsey Protease inhibitors rilpivirine Tenofovir tenofovir alafenamide Source Type: research
Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study.
CONCLUSION: Blips are commonly encountered in the clinical management of HIV-infected patients. Although blip occurrence was not associated with SRA or EFV blood levels in our study, blips were associated with HIV-related factors of pre-ART high VL and low CD4 count. Additional studies are needed to determine the etiology of blips in HIV-infected patients.
PMID: 27006682 [PubMed] (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - March 24, 2016 Category: Infectious Diseases Authors: Farmer A, Wang X, Ganesan A, Deiss RG, Agan BK, O'Bryan TA, Akers K, Okulicz JF Tags: AIDS Res Ther Source Type: research
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus
Conclusion: CVC showed efficacy and favorable safety in treatment-naive HIV-1-infected study participants, supporting selection of CVC200 for phase 3 studies.
Trial registration: NCT01338883. (Source: AIDS)
Source: AIDS - March 15, 2016 Category: Infectious Diseases Tags: Clinical Science Source Type: research
